RSS-Feed abonnieren
DOI: 10.1055/s-0042-1750417
A Silent Threat of Emerging Resistance Based on Antifungal Susceptibility Pattern of Filamentous Fungi by Microdilution, E Test and, Disc Diffusion Method: A Critical Constructive Analysis
Abstract
For more than two decades, antifungal susceptibility testing and interpretation haunted the medical professionals in diagnostics and management. This article mainly focuses on the three most widely used methods: broth microdilution, E test, and disc diffusion. It also focuses on the fact that clinicians should switch from empirical treatment to susceptible drugs as early as possible to combat antifungal resistance and newer mutations that horrify us every single day with poor patient outcomes. Many factors need to be taken into account during the interpretation of results but the positive side of the story is that they have been well documented in the literature. Though many methods have come up in testing antifungal susceptibility, still there is a scope for a rapid yet accurate testing modality to flourish and take the lead.
Publikationsverlauf
Artikel online veröffentlicht:
27. Juni 2022
© 2022. National Academy of Medical Sciences (India). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India
-
References
- 1 CLSI. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Filamentous Fungi; Approved Standard, 2nd ed. CLSI Document M38–A2, Vol 28, No 16. Wayne, PA: Clinical and Laboratory Standards Institute; 2008
- 2 Pfaller MA, Messer SA, Mills K, Bolmström A. In vitro susceptibility testing of filamentous fungi: comparison of Etest and reference microdilution methods for determining itraconazole MICs. J Clin Microbiol 2000; 38 (09) 3359-3361
- 3 Seyedmousavi S, Samerpitak K, Rijs AJ. et al. Antifungal susceptibility patterns of opportunistic fungi in the genera Verruconis and Ochroconis. Antimicrob Agents Chemother 2014; 58 (06) 3285-3292
- 4 Gupta P, Khare V, Kumar D, Ahmad A, Banerjee G, Singh M. Comparative evaluation of disc diffusion and E-test with broth micro-dilution in susceptibility testing of amphotericin b, voriconazole and caspofungin against clinical Aspergillus isolates. J Clin Diagn Res 2015; 9 (01) DC04-DC07
- 5 Linares MJ, Charriel G, Solís F, Rodriguez F, Ibarra A, Casal M. Susceptibility of filamentous fungi to voriconazole tested by two microdilution methods. J Clin Microbiol 2005; 43 (01) 250-253
- 6 Ascioglu S, Rex JH, de Pauw B. et al; Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer; Mycoses Study Group of the National Institute of Allergy and Infectious Diseases. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34 (01) 7-14
- 7 Messer S, Jones R, Fritsche T. International surveillance of Candida spp. and Aspergillus spp.: Report from the SENTRY Antimicrobial Surveillance Program (2003). Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract M-1797
- 8 Herbrecht R, Marr K, Catanzaro A. et al. Posaconazole (POS) as salvage therapy for invasive fungal infections (IFIs) unresponsive to voriconazole: a case series. Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract M-1044
- 9 Stevens D, Rendon A, Gaona V. et al. Posaconazole (POS) therapy for chronic refractory coccidioidomycosis. Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract M-663
- 10 Raad I, Boktour M, Hanna H, Kontoyiannis D, Hachem R. Posaconazole (POS) compared to amphotericin B lipid formulations (AmB/LPD) in combination with caspofungin (CASP) as salvage therapy for invasive aspergillosis (IA) in patients (pts) with hematologic malignancy (HM). Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract M-1035
- 11 Kontoyiannis D, Lionakis M, Lewis R, Walsh T, Raad I. Zygomycosis (Z) in the era of voriconazole (VRC) in a cancer center: a matched case-control observational study of 27 recent patients (pts). Program and abstracts of the 44th Interscience Conference of Antimicrobial Agents and Chemotherapy; October 30 to November 2, 2004; Washington, DC. Abstract M-665
- 12 Macedo D, Leonardelli F, Dudiuk C. et al. Molecular confirmation of the linkage between the Rhizopus oryzae CYP51A gene coding region and its intrinsic voriconazole and fluconazole resistance. Antimicrob Agents Chemother 2018; 62 (08) e00224-e18
- 13 Posch W, Blatzer M, Wilflingseder D, Lass-Flörl C. Aspergillus terreus: novel lessons learned on amphotericin B resistance. Med Mycol 2018; 56 (01, Suppl 1): 73-82
- 14 Pfaller MA, Messer SA, Woosley LN, Jones RN, Castanheira M. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51 (08) 2571-2581
- 15 Khan M, Ikram A, Zaman G, Gardezi A, Lalani FK. Pattern of antifungal susceptibility in pathogenic molds by microdilution method at a tertiary care hospital. Ann Med Health Sci Res 2018; 8: 82-86